CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Long-Acting Beta2-Agonists for Chronic Obstructive Pulmonary Disease: Safety and Harms

Last updated: November 19, 2014
Project Number: RB0754-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the evidence for the safety or harms of long-acting beta2-agonists for patients with chronic obstructive pulmonary disease (COPD), with regards to cardiac arrhythmia?

Key Message

​Twelve randomized controlled trials and five non-randomized studies were identified on the safety or harms of long-acting beta2-agonists for patients with chronic obstructive pulmonary disease, with regards to cardiac arrhythmia.